Kronos Bio

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic malignancies, prostate cancer, MYC-driven cancers, and small cell/neuroendocrine cancers. The company was founded by Angela Koehler and Joshua A. Kazam in 2017 and is headquartered in San Mateo, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.

SAN MATEO, Calif. and CAMBRIDGE, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of veteran biopharmaceutical executive Marianne De Backer, Ph.D., to the company's board of directors. She has more than two decades of experience in business development and commercial leadership in the healthcare industry. Additionally, the company announced that Rebecka Belldegrun, M.D., has resigned from the board to pursue other opportunities.

Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors

MYC amplification found in approximately 30% of solid tumors

Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of N PM1-mutated acute myeloid leukemia

Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Wednesday, Nov. 18, 2020, at 7:20 p.m. GMT (2:20 p.m. ET).

Kronos Bio Announces Participation in the Jefferies Virtual London Healthcare Conference

Carnival

Brookfield Asset Management

FuboTV

HEICO

Shattuck Labs

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when markets are near all-time highs.

Last Week's Notable Insider Buys: Carnival, Citigroup And More

SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced the closing of its previously announced initial public offering of 15,131,579 shares of its common stock, which includes 1,973,684 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $19.00 per share. Including the option exercise, the aggregate gross proceeds to Kronos Bio from the offering were approximately $287.5 million, before deducting the underwriting discounts and commissions and offering expenses. The shares began trading on the Nasdaq Global Select Market on October 9, 2020, under the ticker symbol “KRON.”

Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Intrusion

Mudrick Capital Acquisition

Spruce Biosciences

U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week

Shares of Kronos Bio Inc. soared in their public debut, as they opened 50% above the initial public offering price. The stock's first trade was at $28.50 at 11:58 a.m.

Kronos Bio's stock opens TK% above IPO price

This week has down with 6 IPOS scheduled for Thursday and Friday. FuboTV: Sport first live tv streaming company Fubo TV (OTC: FUBO) is uplisting to the Nasdaq.

FuboTV Uplisting, Kronos Bio Highlight This Week's IPOs

Kronos Bio Inc. priced its upsized initial public offering at $19 a share, above its $16 to $18 price range. The California-based biotech sold 13.2 million shares to raise about $250.8 million.

Kronos Bio prices upsized IPO above range at $19 a share

SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced the pricing of its initial public offering of 13,157,895 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Kronos Bio from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $250.00 million. All of the shares are being offering by Kronos Bio. In addition, Kronos Bio has granted the underwriters a 30-day option to purchase up to an additional 1,973,684 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.

Kronos Bio Announces Pricing of Initial Public Offering

Kronos Bio Inc. KRON, disclosed Thursday that its initial public offering was upsized by about 28%, as the California-based biopharmaceutical now looks to raise up to $236.8 million

Kronos Bio upsizes IPO, boosting valuation to up to $975.5 million

News for Kronos Bio Stock (KRON)